Author:
Fond Guillaume, ,Berna F.,Boyer L.,Godin O.,Brunel L.,Andrianarisoa M.,Aouizerate B.,Capdevielle D.,Chereau I.,Danion J. M.,Dubertret C.,Dubreucq J.,Faget C.,Gabayet F.,Le Gloahec T.,Llorca P. M.,Mallet J.,Misdrahi D.,Rey R.,Richieri R.,Passerieux C.,Portalier C.,Roux P.,Vehier A.,Yazbek H.,Schürhoff F.,Bulzacka E.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,General Medicine
Reference51 articles.
1. Achim AM, Maziade M, Raymond É, Olivier D, Mérette C, Roy M-A (2011) How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 37:811–821. doi:
10.1093/schbul/sbp148
2. Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992) Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6:201–208
3. APA/CAPP Task Force on Serious Mental Illness and Severe Emotional Disturbance (2007) Training grid: best practices for recovery and improved outcomes for people with serious mental illness/serious emotional disturbance
4. Baandrup L, Fagerlund B, Glenthoj B (2016) Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. Eur Arch Psychiatry Clin Neurosci. doi:
10.1007/s00406-016-0711-8
5. Baddeley AD, Emslie H, Nimmo-Smith I (1994) Doors and people: a test of visual and verbal recall and recognition. Thames Valley Test Company, Bury St Edmunds